CAS 666816 98 4 Linagliptin Intermediate GMP Condition C10H9BrN4O2

CAS : 666816-98-4 Linagliptin Intermediate 

Chemical Name : 8 - Bromo -7- ( 2 - butynyl) - 3 , 7- dihydro -3- methyl -3,7- dihydro -3- methyl -1H- purine -2,6- dione

CAS No . : 666816-98-4

Synonym : 3 - Methyl - 7 - ( 2 - butyn - 1 - yl ) - 8 - bromoxanthine

Molecular Formula : C10H9BrN4O2

Molecular Weight : 297.11

Usage : Linagliptin Intermediate

Description: Linagliptin is the active pharmaceutical ingredient (API) of branded drug Tradjenta, Trajenta or Trazenta. It was innovated by the Germany drug maker Boehringer Ingelheim and cooperated the marketing with Lily. Linagliptin was approve by the US FDA in 2011. Linagliptin is used for the treatment of type 2 diabetes. Linagliptinis is a Dipeptidyl peptidase-4 inhibitor (DPP-4, DPP-IV).

8 - Bromo -7- ( 2 - butynyl) - 3 , 7- dihydro -3- methyl -3,7- dihydro -3- methyl -1H- purine -2,6- dione CAS No . : 666816-98-4 is one of its intermediates. There are several synthesis routes to manufacture this intermediate but some routes are protected by the patents in some countries including Europe, USA and China. We strictly obey the laws and our products are for R&D purpose. But anyway, the buyers should know the patent status by themselves. We promise to supply the real route of synthesis to the buyers. The buyers should take the risks of patent infringement by themselves.

Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.